Envisioning the future of early anticancer drug development

The development of novel molecularly targeted cancer therapeutics remains slow and expensive with many late-stage failures. There is an urgent need to accelerate this process by improving early clinical anticancer drug evaluation through modern and rational trial designs that incorporate predictive, pharmacokinetic, pharmacodynamic, pharmacogenomic and intermediate end-point biomarkers. In this article, we discuss current approaches and propose strategies that will potentially maximize benefit to patients and expedite the regulatory approvals of new anticancer drugs.

[1]  D. Dearnaley,et al.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.

[2]  J. Llovet,et al.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.

[3]  E. Crivellato,et al.  Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. , 2008, Cancer letters.

[4]  Mitch Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Evan,et al.  Tumor angiogenesis: cause or consequence of cancer? , 2007, Cancer research.

[6]  R. Kalluri,et al.  Endogenous inhibitors of angiogenesis. , 2005, Cancer research.

[7]  L. Tanoue,et al.  Detection of Mutations in EGFR in Circulating Lung-Cancer Cells , 2010 .

[8]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[9]  C. Köhne,et al.  Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial , 2007 .

[10]  R. Pearson,et al.  Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .

[11]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[12]  L. Forthun,et al.  Final Results , 2009 .

[13]  J. DiMasi,et al.  Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.

[14]  S. Friend,et al.  A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.

[15]  M. Ratain,et al.  Biomarkers in Phase I Oncology Trials: Signal, Noise, or Expensive Distraction? , 2007, Clinical Cancer Research.

[16]  G. Szakács,et al.  Relevance of multidrug resistance in the age of targeted therapy. , 2009, Current opinion in drug discovery & development.

[17]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[18]  Joseph A DiMasi,et al.  Economics of new oncology drug development. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  David Warde-Farley,et al.  Dynamic modularity in protein interaction networks predicts breast cancer outcome , 2009, Nature Biotechnology.

[20]  A. Tutt,et al.  Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Workman.  Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. , 2003, Molecular cancer therapeutics.

[22]  Daniel J Sargent,et al.  Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Paul Workman,et al.  Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma , 2009, Cell cycle.

[24]  H. McLeod,et al.  Pharmacogenomic progress in individualized dosing of key drugs for cancer patients , 2009, Nature Clinical Practice Oncology.

[25]  P. Workman.  How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. , 2003, Current pharmaceutical design.

[26]  G. Ahn,et al.  Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. , 2008, Cancer cell.

[27]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[28]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Sawyers.  The cancer biomarker problem , 2008, Nature.

[30]  P. Workman,et al.  Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development , 2009, Cancer journal.

[31]  J. Ware,et al.  A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  David A. Tuveson,et al.  Maximizing mouse cancer models , 2007, Nature Reviews Cancer.

[33]  Ultan McDermott,et al.  Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Bast,et al.  Project Zero Delay: a process for accelerating the activation of cancer clinical trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Hanahan,et al.  Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.

[36]  K. Gelmon,et al.  Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T , 2007 .

[37]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[38]  Susan Groshen,et al.  The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee , 2010, Clinical Cancer Research.

[39]  C. Takimoto.  Maximum tolerated dose: clinical endpoint for a bygone era? , 2009, Targeted Oncology.

[40]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[41]  P. Workman,et al.  Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 , 2009, Molecular Cancer Therapeutics.

[42]  A. Tutt,et al.  Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Y. Meng,et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.

[44]  J. Clark,et al.  Utility and costs of surrogate endpoints (SEs) and biomarkers in phase I oncology trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Yap,et al.  Targeting the HGF/c-Met Axis: State of Play , 2010, Molecular Cancer Therapeutics.

[46]  M. Ratain,et al.  Pharmacogenetics and pharmacogenomics of anticancer agents , 2009, CA: a cancer journal for clinicians.

[47]  L. Elmore,et al.  Telomerase as a Target for Cancer Immunotherapy , 2003, Cancer biology & therapy.

[48]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[49]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[50]  G. Giaccone,et al.  Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). , 2008, European journal of cancer.

[51]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[52]  M. Birkner,et al.  A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[54]  J. Doroshow,et al.  Drug development in oncology: classical cytotoxics and molecularly targeted agents. , 2006, British journal of clinical pharmacology.

[55]  P. Allavena,et al.  Tumor-Associated Macrophages (TAM) as Major Players of the Cancer-Related Inflammation , 2010 .

[56]  R. Plummer,et al.  Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Ian Collins,et al.  New approaches to molecular cancer therapeutics , 2006, Nature chemical biology.

[58]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[59]  P. Workman,et al.  Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. , 2007, Biomarkers in medicine.

[60]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[61]  Larry Rubinstein,et al.  Randomized Phase II Designs , 2009, Clinical Cancer Research.

[62]  M. Lai,et al.  Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. , 2006, Endocrinology.

[63]  J. Dancey,et al.  A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment , 2009, Journal of the National Cancer Institute.

[64]  Paul Workman,et al.  Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. , 2008, Current opinion in pharmacology.

[65]  D. Hodgson,et al.  Circulating tumour-derived predictive biomarkers in oncology. , 2010, Drug discovery today.

[66]  Suzanne F. Jones,et al.  Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  M. Ratain,et al.  Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Marc Buyse,et al.  Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation , 2006, Pharmaceutical statistics.

[69]  F. Peale,et al.  The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[70]  F. Peale,et al.  Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Cristofanilli.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2006, Seminars in oncology.

[72]  Paul Workman,et al.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic. , 2010, Cancer research.

[73]  C. Sigman,et al.  New science-based endpoints to accelerate oncology drug development. , 2005, European journal of cancer.

[74]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[75]  P. Workman,et al.  Biomarkers In Early Clinical Trials: the Committed and the Skeptics , 2008, Clinical Cancer Research.

[76]  T. Yap,et al.  Targeting CYP17: established and novel approaches in prostate cancer. , 2008, Current opinion in pharmacology.

[77]  N. Ferrara.  Pathways mediating VEGF-independent tumor angiogenesis. , 2010, Cytokine & growth factor reviews.

[78]  Janice M. Reichert,et al.  Development trends for new cancer therapeutics and vaccines. , 2008, Drug discovery today.

[79]  P. Workman,et al.  Cancer: Drug-tolerant insurgents , 2010, Nature.

[80]  C. Lewis,et al.  Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. , 2004, Blood.

[81]  C. Divino,et al.  Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. , 2008, Blood.

[82]  S. Lakhani,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  A. Harris,et al.  Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  M. Christian,et al.  Phase I clinical trial design in cancer drug development. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  A. Adjei,et al.  Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors , 2007, Clinical Cancer Research.

[86]  Timothy A. Yap,et al.  Beyond chemotherapy: targeted therapies in ovarian cancer , 2009, Nature Reviews Cancer.

[87]  Richard Simon,et al.  The Use of Genomics in Clinical Trial Design , 2008, Clinical Cancer Research.

[88]  Paul Workman,et al.  Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. , 2006, Journal of the National Cancer Institute.

[89]  P. Workman,et al.  Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone , 2000, Oncogene.

[90]  P. Fu,et al.  Multi-institutional phase I trials of anticancer agents. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[92]  S. Cannistra.  Challenges and pitfalls of combining targeted agents in phase I studies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[94]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[95]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[96]  P. Workman,et al.  Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. , 2008, Current opinion in pharmacology.

[97]  P. Workman.  Challenges of PK/PD measurements in modern drug development. , 2002, European journal of cancer.

[98]  E. Eisenhauer,et al.  Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. , 2004, Journal of the National Cancer Institute.

[99]  D. Olmos,et al.  Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. , 2009, Cancer research.

[100]  P. Workman,et al.  Cytostasis and Apoptosis 17-Allylamino-17-demethoxygeldanamycin Results in Inhibition of Signal Transduction by the Hsp 90 Inhibitor Updated Version , 2001 .

[101]  G. Demetri,et al.  A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[103]  R. Kerbel,et al.  Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development , 2004, Clinical Cancer Research.

[104]  Alexia Iasonos,et al.  A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies , 2008, Clinical trials.

[105]  N. Spector,et al.  EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  L. Coussens,et al.  The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. , 2005, Cancer research.

[107]  Jeffrey W. Clark,et al.  Trends in the Use and Role of Biomarkers in Phase I Oncology Trials , 2007, Clinical Cancer Research.

[108]  Steven Gutman,et al.  Opinion: The US Food and Drug Administration perspective on cancer biomarker development , 2006, Nature Reviews Cancer.

[109]  A. Adjei.  What is the right dose? The elusive optimal biologic dose in phase I clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  K. Flaherty,et al.  Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  Daniel J Sargent,et al.  Optimising the design of phase II oncology trials: the importance of randomisation. , 2009, European journal of cancer.

[112]  F.A.M. Bordonaba,et al.  Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .

[113]  Antje Hoering,et al.  Randomized Phase III Clinical Trial Designs for Targeted Agents , 2008, Clinical Cancer Research.

[114]  Masahiro Inoue,et al.  An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. , 2004, The Journal of clinical investigation.

[115]  Caroline Dive,et al.  Tumorigenesis and Neoplastic Progression Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy , 2010 .

[116]  P. Workman,et al.  Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino , 17-Demethoxygeldanamycin in Human Ovarian Cancer , 2005 .

[117]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[118]  Paul Workman,et al.  Pharmacodynamic biomarkers for molecular cancer therapeutics. , 2007, Advances in cancer research.

[119]  Nathanael Gray,et al.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors , 2009, Nature Reviews Drug Discovery.

[120]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[121]  Alan Ashworth,et al.  A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  S. Sleijfer,et al.  Dose selection in phase I studies: why we should always go for the top. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  Y. Ohe,et al.  EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  A. Ashworth,et al.  Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.

[126]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[127]  D. Sargent,et al.  Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.